Bristol/ImClone's Erbitux Could Be A First-Line Head And Neck Cancer Submission
This article was originally published in The Pink Sheet Daily
Executive Summary
Companies are also pursuing possible use as a front-line non-small cell lung cancer treatment. The biologic is being studied as fist-line in colorectal cancer as well.